Enanta Pharmaceuticals(NASDAQ) ENTA

Enanta Pharmaceuticals makes drugs to fight viruses and diseases. The company helps people with lung infections and skin conditions. It earns money by licensing its discoveries to other firms.

What Does Enanta Do?

• Hepatitis C Royalties: Payments from AbbVie for the drug MAVYRET/MAVIRET used to treat liver infections; accounts for 100% of revenue.
• Respiratory Syncytial Virus: Experimental oral treatments for lung infections that often affect children and seniors; includes candidates zelicapavir and EDP-323.
• Immunology Programs: Small molecule inhibitors designed to treat skin diseases like hives and atopic dermatitis, a type of eczema.
• Other Virology Targets: Research projects aimed at creating new treatments for the virus that causes COVID-19 and chronic hepatitis B.

Recent Moves and Growth

• Sold 54.5% of future royalty payments from hepatitis C drugs to OMERS in April 2023 for $200 million.
• Secured expanded label approvals for MAVYRET/MAVIRET to treat acute hepatitis C in June 2025 and June 2026.
• Closed a public offering of common stock in October 2025 to support research and development activities.
• Entered an agreement in July 2026 to sell up to $75 million in stock through Jefferies.

Scientific and Operational Strengths

Enanta uses internal chemistry and drug discovery capabilities to create all its own development programs. The company focuses on small molecule therapies that patients can take orally for complex viral and inflammatory diseases.

The Financial Scorecard

• Revenue was $14.4 million for the three months ended June 30, 2026, down from $18.3 million in the same period in 2025.
• Research and development expenses totaled $62.4 million during the nine months ended June 30, 2026.
• Net loss was $19.5 million for the three months ended June 30, 2026.
• Cash, cash equivalents, and marketable securities reached $211.5 million as of June 30, 2026.
• Interest expense rose to $4.1 million in the quarter ended June 30, 2026, compared to $1.6 million in the prior year.

The Big Picture

Enanta has moved from a discovery-focused partner to a developer with several wholly-owned clinical programs. Its expansion into respiratory and inflammatory medicine seeks to build value beyond its original hepatitis C royalty stream.